The AP4E1 Knockout HT29 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout population derived from HT29 human colorectal adenocarcinoma cells, in which the AP4E1 gene has been disrupted. This gene encodes the epsilon subunit of the heterotetrameric adaptor protein complex 4 (AP-4), which orchestrates clathrin-mediated vesicular trafficking from the trans-Golgi network to endosomes and lysosomes. The polyclonal format provides a genetically diverse loss-of-function model that avoids clonal isolation artifacts, making it a versatile tool for examining AP4E1-dependent processes such as protein sorting and autophagy in an intestinal epithelial context.
HT29 cells are a widely employed epithelial line isolated from a primary colorectal adenocarcinoma, retaining characteristic colonocyte features and oncogenic mutations. They serve as a standard in vitro system for investigating intestinal barrier integrity, differentiation, and growth factor signaling. Capable of forming polarized monolayers, HT29 cells enable detailed analysis of membrane traffic pathways that are essential for epithelial polarity and function. In this knockout background, the HT29 line offers a physiologically relevant platform to dissect how AP-4-mediated trafficking influences colonocyte biology and tumor cell behavior.
AP4E1 encodes the largest subunit of the AP-4 complex, which also includes AP4B1, AP4M1, and AP4S1. The complex recognizes tyrosine-based sorting motifs on cargo proteins such as ATG9A, facilitating their delivery from the trans-Golgi network to endolysosomal compartments. Upstream, AP-4 activity is regulated by mTORC1 signaling and cellular nutrient status, while downstream, proper ATG9A transport is critical for autophagosome formation. Disruption of AP4E1 abrogates AP-4 complex assembly and cargo sorting, leading to impaired autophagic flux and lysosomal dysfunction. Consequently, this knockout model uncouples the mTORC1?CAP-4?CATG9A axis, allowing mechanistic dissection of trafficking-dependent degradative pathway control.
Within the HT29 colorectal cancer milieu, AP4E1 loss illuminates the role of endomembrane trafficking in tumor cell homeostasis. Cancer cells often rewire autophagy and lysosomal pathways to sustain proliferation and evade apoptosis; thus, AP4E1 knockout reveals vulnerabilities that may be targeted therapeutically. Moreover, biallelic AP4E1 mutations cause hereditary spastic paraplegia type 47 (AP-4 deficiency syndrome), yet peripheral cellular phenotypes remain underexplored. These polyclonal knockout cells enable cross-disciplinary studies that bridge cancer biology and neurodevelopmental disease modeling, with potential for identifying trafficking modulators or correctors in a tractable epithelial system.
Researchers can apply this AP4E1 knockout HT29 population in multiple experimental workflows. Typical assays include Western blotting for AP-4 subunit expression, immunofluorescence colocalization of lysosomal and autophagosomal markers, LC3 lipidation flux analyses, and flow cytometry-based viability assessments. Co-immunoprecipitation can probe residual complex assembly, while RT-qPCR monitors transcriptional changes of cargo genes. Cell migration and invasion assays evaluate metastatic potential, and electron microscopy visualizes vesicular trafficking defects at ultrastructural resolution. For product inquiries, please contact Ascent Research.
